NOX Activity Is Increased in Mild Cognitive Impairment
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
This study was undertaken to investigate the profile of NADPH oxidase (NOX) in the clinical progression of Alzheimer's disease (AD). Specifically, NOX activity and expression of the regulatory subunit p47phox and the catalytic subunit gp91phox was evaluated in affected (superior and middle temporal gyri) and unaffected (cerebellum) brain regions from a longitudinally followed group of patients. This group included both control and late-stage AD subjects, and also subjects with preclinical AD and with amnestic mild cognitive impairment (MCI) to evaluate the profile of NOX in the earliest stages of dementia. Data show significant elevations in NOX activity and expression in the temporal gyri of MCI patients as compared with controls, but not in preclinical or late-stage AD samples, and not in the cerebellum. Immunohistochemical evaluations of NOX expression indicate that whereas microglia express high levels of gp91phox, moderate levels of gp91phox also are expressed in neurons. Finally, in vitro experiments showed that NOX inhibition blunted the ability of oligomeric amyloid beta peptides to injure cultured neurons. Collectively, these data show that NOX expression and activity are upregulated specifically in a vulnerable brain region of MCI patients, and suggest that increases in NOX-associated redox pathways in neurons might participate in the early pathogenesis of AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide
Haass, C., & Selkoe, D. J. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2101 · Cited by 4,744 · cited 1×
“Evidence suggests that smaller oligomeric A b species correlate well with behavioral deficits and further are potent mediators of synaptotoxicity and neuronal death and [reviewed in (14, 44)].”
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188
Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β-peptide
Butterfield, D. A., Drake, J., Pocernich, C., & Castegna, A. (2001) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(01)02173-6 · Cited by 1,114
In-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054 · cited 1×
“Interestingly, recent PET imaging studies using carbon-11–linked (R)-PK11195 have documented enhanced microglial activation in many MCI patients (7, 46), although other groups have not been successful in detecting enhanced PK11195 binding in MCI subjects (65).”
Mild Cognitive Impairment as a Clinical Entity and Treatment Target
Petersen, R. C., & Morris, J. C. (2005) · Archives of Neurology · doi:10.1001/archneur.62.7.1160 · Cited by 935 · cited 1×
“The diagnosis of MCI is applied to aged persons expressing consistent, measurable memory impairments without dementia or significant disability related to activities of daily living (ADLs) (50, 68).”
Keller, J. N., Kindy, M. S., Holtsberg, F. W., St. Clair, D. K., Yen, H.-C., Germeyer, A., Steiner, S. M., Bruce-Keller, A. J., Hutchins, J. B., & Mattson, M. P. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-02-00687.1998 · Cited by 863
Self-citationKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 1×
“In support of this scenario, A b oligomers have been shown to colocalize with postsynaptic densities, and associate specifically with dendritic spine collapse and synapse loss (31).”
A “mitochondrial cascade hypothesis” for sporadic Alzheimer’s disease
Swerdlow, R. H., & Khan, S. M. (2004) · Medical Hypotheses · doi:10.1016/j.mehy.2003.12.045 · Cited by 758 · cited 1×
“…hypothesis,’’ in which age-related increases in basal mitochondrial ROS production lead to neuronal dysfunction and pathologic hallmarks of AD (61), data in this article support the hypothesis that increased NOX might participate with mitochondria in AD-associated oxidative stress, which is…”
Cited by
Simpson, D. S. A., & Oliver, P. L. (2020) · Antioxidants · doi:10.3390/antiox9080743 · Cited by 1,044
“Further, microglia in AD brains strongly express gp91phox, implying NOX2 activation is localised to microglia in AD [119].”
BackgroundOxidative Stress and Psychological Disorders
Salim, S. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120230309 · Cited by 557
Loane, D. J., Kumar, A., Stoica, B. A., Cabatbat, R., & Faden, A. I. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000021 · Cited by 498
Neuroprotective strategies involving ROS in Alzheimer disease
Dumont, M., & Beal, M. F. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.11.026 · Cited by 402
Functions and dysfunctions of nitric oxide in brain
Picón-Pagès, P., Garcia-Buendia, J., & Muñoz, F. J. (2019) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.11.007 · Cited by 347
Choi, D.-Y., Lee, Y.-J., Hong, J. T., & Lee, H.-J. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.11.014 · Cited by 305
Microglia in Alzheimer Disease: Well-Known Targets and New Opportunities
Hemonnot, A.-L., Hua, J., Ulmann, L., & Hirbec, H. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00233 · Cited by 298
Kumar, A., Stoica, B. A., Sabirzhanov, B., Burns, M. P., Faden, A. I., & Loane, D. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.11.013 · Cited by 244
“NADPH oxidase is implicated in the ongoing pathology of several age-associated neurodegenerative diseases such as Alzheimer’s disease (Bruce-Keller et al., 2010; Shimohama et al., 2000) and Parkinson’s disease (Wu et al.”
BackgroundIs Alzheimer’s disease a systemic disease?
Morris, J. K., Honea, R. A., Vidoni, E. D., Swerdlow, R. H., & Burns, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.04.012 · Cited by 219
Aliev, G., Priyadarshini, M., Reddy, V., Grieg, N. H., Kaminsky, Y., Cacabelos, R., Ashraf, G., Jabir, N. R., Kamal, M. A., Nikolenko, V. N., et al. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131227161303 · Cited by 138
NADPH-oxidase activation and cognition in Alzheimer disease progression
Ansari, M. A., & Scheff, S. W. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.025 · Cited by 131
“Our results again support the previous reports in AD[16] and MCI [15] and extend those findings to include possible changes in other subunits.”
ResultWhich NADPH Oxidase Isoform Is Relevant for Ischemic Stroke? The Case for Nox 2
Kahles, T., & Brandes, R. P. (2013) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.4721 · Cited by 125
Mechanisms of neurodegeneration shared between multiple sclerosis and Alzheimer’s disease
Lassmann, H. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0607-8 · Cited by 112
Vascular and metabolic dysfunction in Alzheimer’s disease: a review
Murray, I. V. J., Proza, J. F., Sohrabji, F., & Lawler, J. M. (2011) · Experimental Biology and Medicine · doi:10.1258/ebm.2011.010355 · Cited by 104
Cognitive impairment in humanized APP×PS1 mice is linked to Aβ1–42 and NOX activation
Bruce-Keller, A. J., Gupta, S., Knight, A. G., Beckett, T. L., McMullen, J. M., Davis, P. R., Murphy, M. P., Van Eldik, L. J., St Clair, D., & Keller, J. N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.07.012 · Cited by 96
“, 2008), (Bruce-Keller et al., 2010), but extend these Bruce-Keller et al.”
InfluentialNuclear and mitochondrial DNA oxidation in Alzheimer's disease
Santos, R. X., Correia, S. C., Zhu, X., Lee, H.-G., Petersen, R. B., Nunomura, A., Smith, M. A., Perry, G., & Moreira, P. I. (2012) · Free Radical Research · doi:10.3109/10715762.2011.648188 · Cited by 57
Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer’s disease
McIntyre, J. A., Ramsey, C. J., Gitter, B. D., Saykin, A. J., Wagenknecht, D. R., Hyslop, P. A., & Initiative, F. T. A. D. N. (2015) · Autoimmunity · doi:10.3109/08916934.2015.1008464 · Cited by 22
“Bruce-Keller and co-workers [22] have reported significant elevations in NADPH oxidase (NOX) activity in the temporal gyri of mild cognitive impairment (MCI) patients.”
Metadata
- Authors
- Bruce-Keller, A. J., Gupta, S., Parrino, T. E., Knight, A. G., Ebenezer, P. J., Weidner, A. M., LeVine, H., Keller, J. N., & Markesbery, W. R.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2010-06-15
- Volume
- 12
- Issue
- 12
- Pages
- 1371-1382
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1996562399
- Cited by
- 104
- References
- 19
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.